department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

EFINACONAZOLE · pharmadog

pharmadog
drugs
EFINACONAZOLE

drug

patient view →

EFINACONAZOLE

Marketedupdated 2mo ago

by Ortho Dermatologics Inc

Approved

community read0 votes

all catalysts(1)

approval · 1

EFINACONAZOLE — FDA approval

News(0)

no news has mentioned this drug yet

brand

EFINACONAZOLE

generic

EFINACONAZOLE

indication

Onychomycosis (Tinea Unguium)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 3, 2028

~1.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

Apr 25, 2035formulationUS 10478601
Oct 2, 2034formulationUS 10342875
Oct 2, 2034method-of-use (U-2720)US 10828293
Oct 2, 2034method-of-use (U-2720)US 10864274
Oct 2, 2034method-of-use (U-1969)US 11654139
Oct 2, 2034formulationUS 9662394
Oct 24, 2030formulationUS 84869784.3y
Oct 24, 2030formulationUS 93020094.3y
Jul 8, 2030formulationUS 101054444.0y
Jul 8, 2030method-of-use (U-281)US 80394944.0y
Jul 8, 2030formulationUS 98616984.0y
Jan 3, 2028method-of-use (U-1969)US 105126401.5y
Jan 3, 2028formulationUS 108283691.5y
Jan 3, 2028method-of-use (U-2720)US 112135191.5y
Jan 3, 2028method-of-use (U-1969)US 118722181.5y
Jan 3, 2028method-of-use (U-1969)US 95662721.5y
Jan 3, 2028method-of-use (U-1969)US 98779551.5y
Feb 22, 2026method-of-use (U-281)US 7214506

Data sources

openFDA · ClinicalTrials.gov

last refreshed just now

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 1

tagApproval2 co-mentions · 1 sources

Trials studying EFINACONAZOLE

phase2A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenailsnot yet recruitingn=200